Business Context and Reporting Period
This Form 8-K Current Report, filed on December 16, 2022, covers events occurring on December 14 and 15, 2022, for Lyell Immunopharma, Inc. (NASDAQ: LYEL). The filing addresses a significant leadership transition involving the departure of the Chief Executive Officer and the appointment of a successor.
Key Financial Metrics
This filing does not contain standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation and separation agreements.
- Severance Package (Ms. Homans): Includes $900,000 in salary continuation (18 months), $360,000 in target bonus (100% of 2022 target), 18 months of COBRA coverage, and up to $25,000 for legal fees.
- New CEO Compensation (Dr. Seely): Annual base salary of $650,000 with a target bonus of up to 60% of base salary.
- Equity Grant (Dr. Seely): Sign-on stock option award for up to 7,500,000 shares, exercisable at the fair market value on December 15, 2022.
Material Changes
The primary material change is the executive leadership transition:
- Departure: Ms. Elizabeth Homans stepped down as Chief Executive Officer and Board member effective December 15, 2022. The filing states there were no disagreements between Ms. Homans and the Company.
- Appointment: Dr. Lynn Seely was appointed President and Chief Executive Officer effective December 15, 2022, while retaining her seat on the Board of Directors.
- Transition Services: Ms. Homans will provide transition services as an independent contractor until June 15, 2024, or earlier termination for cause.
Outlook, Risks, and Unusual Items
Management Commentary: The filing confirms the transition was mutually agreed upon. Dr. Seely brings prior executive experience from Myovant Sciences and Medivation.
Equity Vesting Schedule: Dr. Seely's 7.5 million share option award vests 25% on the first anniversary of her appointment, with the remainder vesting in equal monthly installments thereafter, contingent on continued employment.
Risks/Contingencies: The filing notes that Ms. Homans' severance is subject to a general release and waiver of claims. Dr. Seely's employment is at-will.
Investor Verification Checklist
- Verify the total cash outflow impact of Ms. Homans' separation agreement ($1.26M base + bonus + legal fees).
- Confirm the dilution impact of the 7.5 million share option grant to Dr. Seely relative to the current share count.
- Review the full text of the Separation Agreement (Exhibit 10.1) and Offer Letter (Exhibit 10.2) for additional covenants or acceleration clauses.
- Monitor the Company's press release (Exhibit 99.1) for strategic rationale regarding the leadership change.